User profiles for Palaniappan Kulanthaivel
Palaniappan KulanthaivelVice President, Pyramid Biosciences Verified email at pyramidbio.com Cited by 5430 |
Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non–small cell lung cancer, and other solid tumors
…, AD Fulford, TS Nguyen, R Martinez, P Kulanthaivel… - Cancer discovery, 2016 - AACR
We evaluated the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor
activity of abemaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDK) 4 …
activity of abemaciclib, an orally bioavailable inhibitor of cyclin-dependent kinases (CDK) 4 …
Brain exposure of two selective dual CDK4 and CDK6 inhibitors and the antitumor activity of CDK4 and CDK6 inhibition in combination with temozolomide in an …
TJ Raub, GN Wishart, P Kulanthaivel, BA Staton… - Drug Metabolism and …, 2015 - ASPET
Effective treatments for primary brain tumors and brain metastases represent a major unmet
medical need. Targeting the CDK4/CDK6-cyclin D1-Rb-p16/ink4a pathway using a potent …
medical need. Targeting the CDK4/CDK6-cyclin D1-Rb-p16/ink4a pathway using a potent …
Balanol: a novel and potent inhibitor of protein kinase C from the fungus Verticillium balanoides
P Kulanthaivel, YF Hallock, C Boros… - Journal of the …, 1993 - ACS Publications
Protein kinase C (PKC), a family of serine/threonine-specific kinases, plays a key role in cell
growth, metabolism, and differentiation. 1 Because the activated enzyme has been impli-…
growth, metabolism, and differentiation. 1 Because the activated enzyme has been impli-…
Selective metabolism of vincristine in vitro by CYP3A5
JB Dennison, P Kulanthaivel, RJ Barbuch… - Drug metabolism and …, 2006 - ASPET
Clinical outcomes of vincristine therapy, both neurotoxicity and efficacy, are unpredictable,
and the reported pharmacokinetics of vincristine have considerable interindividual variability. …
and the reported pharmacokinetics of vincristine have considerable interindividual variability. …
A panel of cytochrome P450 BM3 variants to produce drug metabolites and diversify lead compounds
…, MMY Chen, P Kulanthaivel… - … A European Journal, 2009 - Wiley Online Library
Herein we demonstrate that a small panel of variants of cytochrome P450 BM3 from Bacillus
megaterium covers the breadth of reactivity of human P450s by producing 12 of 13 …
megaterium covers the breadth of reactivity of human P450s by producing 12 of 13 …
Metabolism of capsaicin by cytochrome P450 produces novel dehydrogenated metabolites and decreases cytotoxicity to lung and liver cells
…, WJ Ehlhardt, DA Jackson, P Kulanthaivel… - Chemical research in …, 2003 - ACS Publications
Capsaicin is a common dietary constituent and a popular homeopathic treatment for chronic
pain. Exposure to capsaicin has been shown to cause various dose-dependent acute …
pain. Exposure to capsaicin has been shown to cause various dose-dependent acute …
A first-in-human phase I study of the oral p38 MAPK inhibitor, ralimetinib (LY2228820 dimesylate), in patients with advanced cancer
Purpose: p38 MAPK regulates the production of cytokines in the tumor microenvironment
and enables cancer cells to survive despite oncogenic stress, radiotherapy, chemotherapy, …
and enables cancer cells to survive despite oncogenic stress, radiotherapy, chemotherapy, …
Discovery of cercosporamide, a known antifungal natural product, as a selective Pkc1 kinase inhibitor through high-throughput screening
…, G Zhu, RM Campbell, TS Park, P Kulanthaivel… - Eukaryotic …, 2004 - Am Soc Microbiol
The Pkc1-mediated cell wall integrity-signaling pathway is highly conserved in fungi and is
essential for fungal growth. We thus explored the potential of targeting the Pkc1 protein …
essential for fungal growth. We thus explored the potential of targeting the Pkc1 protein …
[HTML][HTML] Novel lipoglycopeptides as inhibitors of bacterial signal peptidase I
P Kulanthaivel, AJ Kreuzman, MA Strege… - Journal of Biological …, 2004 - ASBMB
Signal peptidase (SPase) I is responsible for the cleavage of signal peptides of many secreted
proteins in bacteria. Because of its unique physiological and biochemical properties, it …
proteins in bacteria. Because of its unique physiological and biochemical properties, it …
[HTML][HTML] A population pharmacokinetic and pharmacodynamic analysis of abemaciclib in a phase I clinical trial in cancer patients
SC Tate, AK Sykes, P Kulanthaivel, EM Chan… - Clinical …, 2018 - Springer
Background and Objectives Abemaciclib, a dual inhibitor of cyclin-dependent kinases 4 and
6, has demonstrated clinical activity in a number of different cancer types. The objectives of …
6, has demonstrated clinical activity in a number of different cancer types. The objectives of …